Strategic radiotherapy: a new proof of concept

This publication has 12 references indexed in Scilit:

• Survival Without Quality of Life Deterioration in the GORTEC 2014-04 “OMET” Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR
  International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2024
• Stereotactic Ablative Radiation Therapy for Oligometastatic Ovarian Cancer Lymph Node Disease: The MITO-RT3/RAD Phase II Trial
  International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2024
• Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer
  JNCI: Journal of the National Cancer Institute, 2022
• Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer
  JAMA Oncology, 2020
• Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
  The Lancet Oncology, 2020
• Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
  The Lancet, 2019
• Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer
  JAMA Oncology, 2017
• DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
  Nature Communications, 2017
• Treatment Options in Oligometastatic Disease: Stereotactic Body Radiation Therapy - Focus on Colorectal Cancer
  Visceral Medicine, 2017
• Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
  The Lancet Oncology, 2016